Clinical evidence dossier
Hybrid closed-loop system
HbA1c
Evidence signal
Evidence signal
Strong
This is an authoritative evidence signal supplied by Clinical Reference. It is not a formal clinical grade, treatment recommendation, or pooled effect estimate.
Evidence snapshot
- Authoritative support records
- 7
- Supporting studies available for review
- 7
- Randomized trials
- 7
- Reported effects
- 9
Clinical conclusion
Hybrid closed-loop system shows a strong positive evidence signal for improving HbA1c across the studied comparisons.
Observed effects
Observed study estimates; not a pooled treatment effect.
Between-group effect
Absolute change
−0.9% to −0.4%
Change from baseline
Mean difference
−1.1% to −0.2%
Between-group effect
Mean difference
−1.24% to 0%
Between-group effect
Mean difference
−34 mmol/mol to −34 mmol/mol
Evidence composition
- Non-randomized studies
- 0
- Other designs
- 0
- Unresolved designs
- 0
- Magnitude-eligible effects
- 8
Consistency
Consistency classification
Consistent
- Positive
- 7
- No effect
- 0
- Mixed
- 0
- Negative
- 0
Population and applicability
Structured population data were available for 7 of 7 supporting studies. 7 studies described participants with type 1 diabetes. Age groups were heterogeneous: 3 studies with adult participants, 1 studies with youth participants.
This population information refers to the materialized supporting studies available for review. Omitted support records remain part of the authoritative support accounting and are available through the audit experience.
View reported population descriptions
These descriptions are reported across the supporting studies; they are not a single synthesized population.
- Adults aged 18 and older with type 1 diabetes.
- Individuals currently managing diabetes with insulin therapy.
- Participants starting advanced hybrid closed-loop therapy.
- Young individuals aged 12-25 with type 1 diabetes.
- Patients currently using or considering automated insulin delivery systems.
- Participants currently using insulin therapy.
- Very young children diagnosed with type 1 diabetes.
- Patients requiring insulin therapy for blood sugar management.
- Adults with type 1 diabetes.
- Individuals seeking alternatives to standard clinical practice.
- Adults diagnosed with Type 1 diabetes.
- Individuals currently using insulin pump therapy.
Limitations
- Evidence uses heterogeneous comparison contexts: active_comparator, usual_care.
Supporting evidence
Inspect the authoritative studies and omitted support records for this dossier.